Retest of 002 and beyond will coincide with renewed interest and news of significant progress from the company. Until then, PPS cannot sustain the dilution as volume drops off. We see this pattern again and again in the OTC.
OTC is begging for a massive winner/runner but is this company the one? I don't think so given their less than impressive product line in a saturated market along with a flimsy management team and virtually NO sales.
News 
Market Data 
Discover 
